One academic research institution holds the largest share of ranked families in this dataset, with 45 against a fifth-place count of just 4. That institution’s early circular-vector filings, including the foundational US20040214329A1 lineage, are also the most-cited documents in the field. Commercial biotech assignees hold smaller, more specific portfolios layered on top of that foundational work, so any freedom-to-operate check should start with the leading institution’s claims before looking at the smaller players.

Filings grew 50% from 2021 to 2024, rising from 2 to 3 records, with the field’s peak year at 11 records in 2022. Any apparent decline after 2024 reflects publication lag rather than a real slowdown, since patent publication typically trails actual filing by around 18 months. A fair read of the data through 2024 shows continued, if uneven, activity rather than a plateau.

In this dataset, both terms are searched together because the underlying claims overlap heavily around recombinase-mediated production, residual parental plasmid removal and purification for volumetric yield. Minicircle DNA specifically refers to vectors produced by in-vivo recombinase excision of a bacterial backbone, while minimal vector is a broader term that can include other backbone-reduction approaches. Patent claims in this field rarely separate the two cleanly, so a search strategy that covers both terms captures the full production-method claim space.